Search This Blog

1

Labels

Cancer (150) Breast (38) Study (38) Health (32) Patients (31) Treatment (27) Could (23) Therapy (19) Research (17) Against (12) Blood (11) Disease (11) linked (11) Diabetes (10) Early (10) Prevent (10) Survival (10) Treatments (7) higher (7) surgery (7) Might (6) Prostate (6) Tumors (6) During (5) Effects (5) Growth (5) Chemotherapy (4) Drinking (4) Prevention (4) Obama (3) Obesity (3) Without (3) associated (3) Experts (2) Important (2) Infection (2) About (1) Analysis (1) Causes (1) Eliminate (1) stroke (1)

AD

Sunday, September 22, 2013

A boost for cellular profiling

Sep. 22, 2013 — A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell -- a capability of relevance to everything from basic research to future cancer diagnostics.

"There are cells in tumors and in healthy tissues that are not present in sufficient numbers to permit analysis using anything but single-cell methods," explains senior author, Rickard Sandberg, PhD. "This method allows us to identify rare and important subpopulations of cells in all sorts of tissues. We can also use it to tease apart, more rigorously than ever before, how the expression of unique suites of genes transform cells from one state to another as, say, an embryo develops into an organism, or a tumor becomes metastatic."

Traditional approaches, which depend on the collective analysis of gene expression in millions of cells at once, tend to obscure biologically significant differences in the genes expressed by specialized cells within a particular kind of tissue. Single-cell analysis of gene expression overcomes this limitation. The leading method for such analysis -- Smart-seq -- was developed in 2012 by the biotechnology firm Illumina, together with Sandberg's laboratory.

To develop the new technique, named Smart-seq2, Sandberg's team conducted more than 450 experiments to improve upon their initial method. The new procedure consistently captures three to four times as many RNA molecules, which often translates into 2,000 more genes per cell than current methods allow. It also captures far more full-length gene sequences, a steep challenge in such studies, which often capture only partial sequences of expressed genes. This will permit researchers to conduct a more granular analysis of how subtle differences between the same genes in different people -- known as single nucleotide polymorphisms (or SNPs) -- contribute to differences in biology and disease.

The new method is likely to be of great value to cancer research. Identifying rare sub-populations of cells in tumors and understanding their role in the survival and progression of cancers can provide invaluable information for the development of diagnostics and targeted therapies. A study recently published by Ludwig researchers described, for example, how certain subpopulations of cells in melanomas can be pushed into a drug-susceptible state and then destroyed by chemotherapy. More such strategies might be devised as researchers get a better handle on the cellular species found in different types of tumors, and the patterns of gene expression that define them.

Because Smart-seq2 relies on off-the-shelf reagents, it costs roughly a twentieth as much as the commercialized kit, which should allow researchers to conduct sophisticated analyses of single cells on a much larger scale. It can also be improved further by the scientific community, since its constituent components and rationale are both open to the public.

Armed with the more effective and affordable Smart-seq2, Sandberg's lab is now moving ahead on projects that require a large-scale, single-cell gene expression analysis. "Now all researchers can do their own single-cell gene expression analysis by buying the components of the process described in this paper and assembling their own kits," says Sandberg.


View the original article here

Tackling fears 'while you sleep'

Woman asleepDeep sleep is a time where we consolidate memories

US researchers suggest smells could be used to calm fears - while people sleep.

People were trained to associate two images, linked to smells, with fear.

During sleep they were exposed to one of those smells - and when they woke they were less frightened of the image linked to that smell.

A UK expert praised the Nature Neuroscience study and said it could help treat phobias and perhaps even post-traumatic stress disorders.

People with phobias are already commonly treated with "gradual exposure" therapy while they are awake, where they are exposed to the thing they are frightened of in incremental degrees.

This study suggests that the theory could be extended to therapy while they are in slow-wave, or deep, sleep.

This is the deepest period of sleep, where memories, particularly those linked to emotions, are thought to be processed.

Brain changes

The researchers showed 15 healthy people pictures of two different faces.

At the same time they were given a mild electric shock. They were also exposed to a specific smell, such as lemon, mint, new trainers, clove or wood.

They were then taken into a sleep lab. While they were in slow-wave sleep they were exposed to a smell linked to one of the faces they had been shown.

Later, when they were awake, they were shown both faces - without the scents or shocks.

They showed less fear when shown the face linked to the scent they had smelt while asleep than when shown the other face.

Their response was measured through the amount of sweat on the skin and fMRI (functional magnetic resonance imaging) brain scans.

These showed changes in the areas linked to memory, such as the hippocampus, and in patterns of brain activity in regions associated with emotion, such as the amygdala.

People were in slow-wave sleep for between five and 40 minutes, and the effect was strongest for those who slept for longest.

'Just one day'

Dr Katherina Hauner, of the Northwestern University Feinberg School of Medicine, Chicago, who led the study, said: "It's a novel finding. We showed a small but significant decrease in fear.

"If it can be extended to pre-existing fear, the bigger picture is that, perhaps, the treatment of phobias can be enhanced during sleep."

She said phobias would be the most obvious area to pursue, as cues tended to be relatively simple, compared with the more complex post-traumatic stress disorder (PTSD).

And she said much more research was needed to fully understand the effects this therapy could have.

"This was just one day. We really need to see if it can last weeks, months or years."

'Triggers include smells'

Jennifer Wild, consultant clinical psychologist at the King's College London Institute of Psychiatry, said: "The sleep study is excellent and has implications for treating phobias and stress disorders, such as post-traumatic stress, where there are a whole range of cues.

"Many people who have survived traumatic events, such as fires or road traffic accidents, have a physiological fear response to triggers of their memories.

"Triggers often include smells, such as smoke, petrol, antiseptic smells and alcohol. Infusing these smells during periods of slow-wave sleep could help to extinguish the fear response."

Dr Wild added that the theory could perhaps be extended by exposing people to subtle sounds linked to phobias or traumatic memories during their sleep.


View the original article here

Former U.S. football star Gale Sayers sues NFL over head trauma

By Brendan O'Brien

(Reuters) - Chicago Bears great Gale Sayers has filed a federal lawsuit against the National Football League, accusing it of failing to warn him about and protect him against head injuries, including multiple concussions, during his eight-year Hall of Fame career.

The lawsuit, filed in a Chicago federal court on Friday, comes three weeks after the league agreed to pay $765 million to settle a lawsuit brought by thousands of players, many suffering from dementia and health problems, who accused the league of hiding the dangers of brain injuries.

Sayers, 70, suffers from headaches, occasional short-term memory loss and other cognitive deficits as a result of repeated head trauma, including multiple concussions he endured while playing in the NFL, according to the suit.

Sayers accuses the NFL of not warning him that playing through concussions and brain traumas could and would cause permanent brain damage, according to the lawsuit.

He also says the NFL, on numerous occasions, failed to enact sufficient return-to-play policies, allowing and encouraging him after suffering concussions to return to game action or practice.

The lawsuit accuses helmet maker Riddell of failing to warn him of the risks of concussions, and of not disclosing that the helmets would not prevent concussions.

The lawsuit asks Riddell to pay Sayers $50,000 and court costs. It does not specify damages against the NFL.

Sayers, known as the Kansas Comet, played running back for Chicago from 1965 to 1972, when he retired in the preseason. Sayers led the league twice in rushing and was a four-time Pro Bowler during his career that was cut short by knee injuries.

Sayers was inducted into the Pro Football Hall of Fame in 1977.

In 1970 he published a memoir, "I am Third," describing his rise to football glory and his friendship with Chicago Bears teammate Brian Piccolo, who died of cancer. The autobiography was the basis for the 1971 film, "Brian's Song."

(Reporting By Brendan O'Brien; Editing by Karen Brooks and Xavier Briand)


View the original article here

Propofol discovery may aid development of new anesthetics

Sep. 22, 2013 — Researchers at Washington University School of Medicine in St. Louis and Imperial College London have identified the site where the widely used anesthetic drug propofol binds to receptors in the brain to sedate patients during surgery.

Until now, it hasn't been clear how propofol connects with brain cells to induce anesthesia. The researchers believe the findings, reported online in the journal Nature Chemical Biology, eventually will lead to the development of more effective anesthetics with fewer side effects.

"For many years, the mechanisms by which anesthetics act have remained elusive," explained co-principal investigator Alex S. Evers, MD, the Henry E. Mallinckrodt Professor and head of the Department of Anesthesiology at Washington University. "We knew that intravenous anesthetics, like propofol, act on an important receptor on brain cells called the GABA-A receptor, but we didn't really know exactly where they bound to that receptor."

Propofol is a short-acting anesthetic often used in patients having surgery. It wears off quickly and is less likely to cause nausea than many other anesthetics. But the drug isn't risk-free. Its potentially dangerous side effects include lowering blood pressure and interfering with breathing.

In an attempt to understand how propofol induces anesthesia during surgery, scientists have tried to identify its binding site within the gamma-aminobutyric acid type A (GABA-A) receptor on brain cells. Activating these receptors -- with propofol, for example -- depresses a cell's activity.

Researchers have altered the amino acids that make up the GABA-A receptor in attempts to find propofol's binding site, but Evers said those methods couldn't identify the precise site with certainty.

"In previous work to directly identify anesthetic binding sites, GABA-A receptors had to be extracted from membranes and purified prior to performing the binding studies," he said. "Our method allowed us to study propofol binding to the intact receptor in its native membrane environment."

Having developed the techniques to analyze the interactions between anesthetics and GABA-A receptors in their native environment, Evers' laboratory teamed up with a group at Imperial College that had been taking the same approach. Led by Nicholas P. Franks, PhD, professor of biophysics and anaesthetics, the group has spent years creating a photoanalogue of propofol that both behaves in precisely the same way as propofol and contains a labeling group that permanently attaches to its binding site on the GABA-A receptor when exposed to a specific wavelength of light.

In creating the analogue of propofol, it's as if the researchers put a tiny hook onto the molecule so that when it binds to the GABA-A receptor, it grabs onto the receptor and won't let go.

"Normally, an anesthetic drug binds to the GABA-A receptor transiently," Franks explained. "But for the purposes of this research, we wanted to create an analogue that behaved exactly like propofol except that we could activate this chemical hook to permanently bind the drug to the receptor. The next step was then to extract the receptor, cut it into pieces and identify the precise piece of the protein where the propofol analogue had attached to the receptor. This was the tricky step that the Evers group at Washington University had perfected."

Evers and Franks believe this technique has implications beyond propofol and other anesthetics.

"Anesthetics have desirable effects -- they induce anesthesia, for example -- but they also have undesirable effects," Evers said. "Propofol can lower blood pressure or interfere with breathing, for example. By understanding precisely what the binding sites look like on the proteins that induce those potential problems, we eventually hope to design and select for drugs that have the benefits we want without dangerous side effects."

Using the techniques they have developed, Evers and Franks now plan to identify binding sites of other anesthetic agents. They believe their approach also can be used to study other types of drugs, such as psychiatric agents and anti-seizure drugs.


View the original article here

Washington U researchers have developed a new model of drug resistance in breast cancer treatment tips for better.

May be researchers in medicine, Washington University in St. Louis were transplanted into human breast cancer tumors are a valuable tool in search models of metastatic carcinoma of superior and better treatments are shown.

View the original article here

Researchers identify switch that controls growth of most aggressive brain tumor cells

Sep. 20, 2013 — Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and aggressive malignant brain tumor.

Findings of their investigation show that the protein RIP1 acts as a mediator of brain tumor cell survival, either protecting or destroying cells. Researchers believe that the protein, found in most glioblastomas, can be targeted to develop a drug treatment for these highly malignant brain tumors. The study was published online Aug. 22 in Cell Reports.

"Our study identifies a new mechanism involving RIP1that regulates cell division and death in glioblastomas," said senior author Dr. Amyn Habib, associate professor of neurology and neurotherapeutics at UT Southwestern, and staff neurologist at VA North Texas Health Care System. "For individuals with glioblastomas, this finding identified a target for the development of a drug treatment option that currently does not exist."

In the study, researchers used animal models to examine the interactions of the cell receptor EGFRvIII and RIP1. Both are used to activate NFκB, a family of proteins that is important to the growth of cancerous tumor cells. When RIP1 is switched off in the experimental model, NFκB and the signaling that promotes tumor growth is also inhibited. Furthermore, the findings show that RIP1 can be activated to divert cancer cells into a death mode so that they self-destruct.

According to the American Cancer Society, about 30 percent of brain tumors are gliomas, a fast-growing, treatment-resistant type of tumor that includes glioblastomas, astrocytomas, oligodendrogliomas, and ependymomas. In many cases, survival is tied to novel clinical trial treatments and research that will lead to drug development.


View the original article here

Governments to agree increased focus on people with disabilities in development strategies

WHO welcomes the forthcoming agreement at a High-Level Meeting at the United Nations General Assembly which will further improve access to health care and related services for people with disabilities and ensure that they are able to contribute to the sustainable development of their communities.

On 23 September, Heads of State – in their first-ever global meeting on this topic – are scheduled to recommend:

  • including people with disabilities in the setting and implementation of development agendas post-2015;
  • addressing the many barriers people with disabilities face in daily life – such as difficulties in accessing health-care services, including rehabilitation and assistive devices;
  • taking urgent action by all stakeholders, including the health sector, to ensure that all development policies benefit people with disabilities;
  • improving collection and analysis of data on disability and devising ways to use it more effectively to guide development policies and programmes.

Improving access to health care

The more than 1 billion people living worldwide with disabilities all have the same general health needs as non-disabled people – such as immunization, cancer screening and reproductive health services. They may also have specific disability-related health conditions, such as ulcers, urinary tract infections, paralysis and depression associated with spinal cord injury. Many people with disabilities require rehabilitation, such as support to regain strength following hospitalization for diabetic coma or provision of a prosthesis after a limb amputation.

“Too often, people with disabilities face barriers in accessing health and rehabilitation services,” says Dr Margaret Chan, Director-General of WHO. “These include stigma and discrimination, lack of accessibility, and the inability to pay. The new UN agreement can help bring down such barriers.”

Today, people with disabilities are twice as likely to report that health care providers’ skills and facilities do not meet their needs. They are three times more likely to be denied health care and four times more likely to be treated badly in the health care system than people without disabilities.

Half the people living with disabilities worldwide are unable to afford the health care they need. They are 50% more likely than persons without disability to suffer catastrophic health expenditure, which pushes them into poverty.

Many people with disabilities are unable to access the assistive devices and related rehabilitation services they need. For example, 360 million people have moderate to profound hearing loss, but production of hearing aids meets only 10% of global need and 3% of developing country need; 200 million people need spectacles or low vision devices, but have no access to them. Some 70 million people need a wheelchair, yet only 5-15% have access to one.

The High-Level Meeting outcome document highlights the importance of:

  • making quality health services available and affordable to people with disabilities, whoever they are and wherever they live;
  • developing national disability policies and programmes that address the health and rehabilitation needs of people with disabilities, and allocating appropriate resources;
  • improving data to better understand these health and rehabilitation needs and monitor and evaluate the impact of policies and programmes.

WHO is already scaling up efforts in line with the outcome document by preparing a seven-year global action plan "Better health for persons with disabilities". The action plan is based on approaches that have proved effective in improving the health and well-being of people with disability.

The draft plan also builds on the Convention on the Rights of Persons with Disabilities and the recommendations of the "World report on disability" (2011). It is currently being reviewed through a series of regional and targeted consultations and on an online consultation process which ends on 11 October 2013. It will be presented to the WHO Executive Board meeting in January 2014 in preparation for consideration at the Sixty-seventh World Health Assembly in May 2014.

For more information please contact:

Gregory Hartl
Coordinator
News, Social Media and Monitoring, WHO
Telephone: +41 22 7914458
Mobile: +41 79203 6715
E-mail: hartlg@who.int


View the original article here

Wealthy Chinese seek U.S. surrogates for second child, green card

By Alexandra Harney

(Reuters) - Wealthy Chinese are hiring American women to serve as surrogates for their children, creating a small but growing business in $120,000 "designer" American babies for China's elite.

Surrogacy agencies in China and the United States are catering to wealthy Chinese who want a baby outside the country's restrictive family planning policies, who are unable to conceive themselves, or who are seeking U.S. citizenship for their children.

Emigration as a family is another draw - U.S. citizens may apply for Green Cards for their parents when they turn 21.

While there is no data on the total number of Chinese who have sought or used U.S. surrogates, agencies in both countries say demand has risen rapidly in the last two years.

U.S. fertility clinics and surrogacy agencies are creating Chinese-language websites and hiring Mandarin speakers.

Boston-based Circle Surrogacy has handled half a dozen Chinese surrogacy cases over the last five years, said president John Weltman.

"I would be surprised if you called me back in four months and that number hadn't doubled," he said. "That's the level of interest we've seen this year from China and the very serious conversations we've had with people who I think will be joining us in the next three or four months."

The agency, which handles about 140 surrogacy cases a year, 65 percent of them for clients outside the United States, is opening an office in California to better serve clients from Asia which has easier flight connections with the West Coast. Weltman said he hopes to hire a representative in Shanghai next year.

The increased interest from Chinese parents has created some cultural tensions.

U.S. agency staff who ask that surrogates and intended parents develop a personal relationship have been surprised by potential Chinese clients who treat surrogacy as a strictly commercial transaction.

In China, where surrogacy is illegal, some clients keep the fact that their baby was born to a surrogate a secret, going so far as to fake a pregnancy, agents say.

CITIZENSHIP DRAW

Chinese interest in obtaining U.S. citizenship is not new. The 14th Amendment to the U.S. constitution gives anyone born in the United States the right to citizenship.

A growing number of pregnant Chinese women travel to America to obtain U.S. citizenship for their children by delivering there, often staying in special homes designed to cater to their needs.

While the numbers are unclear, giving birth in America is now so commonplace that it was the subject of a hit romantic comedy movie, "Finding Mr Right", released in China in March.

Overall, the number of Chinese visitors to the United States nearly doubled in recent years, from 1 million in 2010 to 1.8 million in 2012, U.S. immigration statistics show.

Weltman said that prospective Chinese clients almost always want to chose U.S. citizenship for their babies, while other agencies pointed to a desire to have children educated in the United States.

Some wealthy Chinese say they want a bolt-hole overseas because they fear they will the targets of public or government anger if there were more social unrest in China. There is also a perception that their wealth will be better protected in countries with a stronger rule of law.

At least one Chinese agent promotes surrogacy as a cheaper alternative to America's EB-5 visa, which requires a minimum investment in a job creating business of $500,000.

While the basic surrogacy package Chinese agencies offer costs between $120,000 and $200,000, "if you add in plane tickets and other expenses, for only $300,000, you get two children and the entire family can emigrate to the U.S.," said a Shanghai-based agent.

That cost still means the surrogacy alternative is available only to the wealthiest Chinese.

Intended parents typically pay the surrogate between $22,000 and $30,000, an agency fee of about $17,000 to $20,000 and legal fees of up to $13,000. If egg donation is required, that can cost an additional $15,000 and pre-natal care and delivery fees can run between $9,000 and $16,000.

Indeed, surrogacy in the United States is so expensive that in recent years hundreds of American parents have reportedly turned to surrogates in India.

CHINESE BABIES, AMERICAN WOMBS

Often it is infertility that sends Chinese couples to U.S. surrogacy agencies. More than 40 million Chinese are now considered infertile, according to the Chinese Population Association. The incidence of infertility has quadrupled in the last two decades to 12.5 percent of people of childbearing age.

Shanghai businessman Tony Jiang and his wife Cherry were among them. They turned twice to domestic surrogates after struggling and failing to conceive on their own. Both attempts were unsuccessful, and left them unimpressed with the impersonal nature of in-vitro fertilization (IVF) treatment in China.

Jiang researched surrogacy in Thailand, India and the Ukraine before settling on the United States, in part because of its superior healthcare system.

In December 2010, he and his wife welcomed a daughter, born in California to an American surrogate he calls "my Amanda". The same surrogate later carried twins for the couple.

Friends began to ask him to help them do the same thing and in 2012, he set up his own agency, DiYi Consulting. He has handled 75 surrogacy cases for Chinese parents so far.

Agents said that while many of their clients struggle with infertility, a substantial portion already have one child - some in their teens - and are looking to have a second outside China's 1979 family planning policy that restricts couples, in most cases, to one child.

They count among their clients government officials and employees of state-owned enterprises, for whom a second child would be a fireable offence. Members of the Chinese Communist Party would also face disciplinary action if a second child were reported.

Families who violate the one-child policy face the prospect of forced abortions, sterilizations and fines, policies that have been most brutally enforced in poor, rural areas.

Technically, Chinese who deliver their second child overseas still violate family planning policies, but in practice the government has little way to enforce this, says Zhong Tao, a Shanghai-based lawyer who has handled similar cases.

Obtaining a Chinese household registration, which is necessary to enjoy subsidized health care and enroll for lower tuition as a local student in state schools, is more complicated, if not impossible for second children.

For children who are foreign citizens, parents must apply for visas and residence permits.

BESPOKE BABIES

Seeking surrogacy overseas is not in itself illegal, and Chinese surrogacy agency websites, often adorned with pictures of chubby infants, highlight the possibility of bespoke babies.

Chinese surrogacy clients typically want to use their own eggs and sperm, which allows them to have a child who is fully biologically theirs, agents said.

A growing number, though, are open to egg donation. Often Chinese donors will seek ethnically Chinese or Asian egg donors, commonly with Ivy League degrees.

But others want tall, Eurasian children, agents said. "Lots of clients that are Chinese do use tall blond donors," said Jennifer Garcia, case coordinator at Extraordinary Conceptions, a Carlsbad, California-based agency where 40 percent of clients are Chinese.

Agents said that clients believe these taller, bi-racial children will be smarter and better looking.

Chinese clients also often request boys, a consequence of a cultural preference for boy children. While sex-selective abortion is illegal - though still common - in China, gender selection is technically straightforward through IVF in the United States, where it is used in surrogacy cases.

Genetic screening also allows intended parents to rule out inherited conditions. "You can basically make a designer baby nowadays," said Garcia.

(Additional reporting by Christine Chan in Singapore; Editing by Alex Richardson)


View the original article here

Scientists closer to universal flu vaccine after pandemic 'natural experiment'

Sep. 22, 2013 — Scientists have moved closer to developing a universal flu vaccine after using the 2009 pandemic as a natural experiment to study why some people seem to resist severe illness.

Researchers at Imperial College London asked volunteers to donate blood samples just as the swine flu pandemic was getting underway and report any symptoms they experienced over the next two flu seasons.

They found that those who avoided severe illness had more CD8 T cells, a type of virus-killing immune cell, in their blood at the start of the pandemic.

They believe a vaccine that stimulates the body to produce more of these cells could be effective at preventing flu viruses, including new strains that cross into humans from birds and pigs, from causing serious disease.

The findings are published in Nature Medicine.

Professor Ajit Lalvani from the National Heart and Lung Institute at Imperial College London, who led the study, said: "New strains of flu are continuously emerging, some of which are deadly, and so the Holy Grail is to create a universal vaccine that would be effective against all strains of flu."

Today's flu vaccines make the immune system produce antibodies that recognise structures on the surface of the virus to prevent infection with the most prevalent circulating strains. But they are usually one step behind as they have to be changed each year as new viruses with different surface structures evolve.

Previously, experimental models had suggested that T cells may protect against flu symptoms but until now this idea has not been tested in humans during a pandemic.

Professor Lalvani's team rapidly recruited 342 staff and students at Imperial to take part in their study in autumn 2009. The volunteers donated blood samples and were given nasal swabs. They were sent emails every three weeks asking them to fill in a survey about their health. If they experienced flu symptoms, they took a nasal swab and sent it back to the lab.

They found that those who fell more severely ill with flu had fewer CD8 T cells in their blood, and those who caught flu but had no symptoms or only mild symptoms had more of these cells.

Professor Lalvani said, "The immune system produces these CD8 T cells in response to usual seasonal flu. Unlike antibodies, they target the core of the virus, which doesn't change, even in new pandemic strains. The 2009 pandemic provided a unique natural experiment to test whether T cells could recognise, and protect us against, new strains that we haven't encountered before and to which we lack antibodies.

"Our findings suggest that by making the body produce more of this specific type of CD8 T cell, you can protect people against symptomatic illness. This provides the blueprint for developing a universal flu vaccine.

"We already know how to stimulate the immune system to make CD8 T cells by vaccination. Now that we know these T cells may protect, we can design a vaccine to prevent people getting symptoms and transmitting infection to others. This could curb seasonal flu annually and protect people against future pandemics."


View the original article here

Racism Takes a Toll on Kids' Mental Health, Research Shows

SUNDAY, Sept. 22 (HealthDay News) -- Being a victim of racism may trigger poor mental health, depression and anxiety in children and teens, according to a new review.

The report, published in the October issue of the journal Social Science & Medicine, looked at 461 cases of links between racism and the health and well-being of youngsters.

"The review showed there are strong and consistent relationships between racial discrimination and a range of detrimental health outcomes such as low self-esteem, reduced resilience, increased behavior problems and lower levels of well-being," lead researcher Naomi Priest, of the University of Melbourne in Australia, said in a university news release.

Most of the racism experienced by children and teens involved discrimination by other people, rather than institutional or systemic racism, according to the findings.

The review also revealed an increased risk of poorer birth outcomes among children whose mothers experienced racism during pregnancy.

Most of the studies included in the review were conducted in the United States with participants aged 12 to 18. Of the racial/ethnic groups included in the studies, the three most common were blacks, Hispanics and Asians.

"We know that children who experience poor health and well-being are less likely to engage in education, employment and other activities that support them to lead healthy and productive lives, and to participate meaningfully in the community," Priest said.

So, she noted, the findings identify an important issue that needs to be addressed in order to improve child and teen health.

More information

CivilRights.org explains the importance of talking to children about racism and diversity.

Copyright c 2013?HealthDay. All rights reserved.


View the original article here